Top 50 Ai For Drug Discovery in Latin America

The startup develops personalized pharmaceutical technology that tailors medication regimens based on individual patient profiles, enhancing therapeutic efficacy and minimizing adverse effects. By utilizing advanced data analytics and pharmacogenomics, the company aims to improve patient outcomes and overall quality of life.

Nintx Next Innovative Therapeutics utilizes proprietary technologies such as xGIbiomics, which simulates the human gastrointestinal system, and GAIApath, an AI-driven analytics platform, to identify and develop plant-based therapies targeting multifactorial diseases. By leveraging Brazil's rich biodiversity, Nintx aims to create multi-target therapies that modulate human biological systems and the microbiome, addressing the limitations of traditional single-target drug approaches.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

Onc.AI develops an AI-powered clinical management platform that utilizes a comprehensive oncology real-world dataset, including diagnostic imaging and genomics, to enhance treatment decision-making for metastatic lung cancer patients undergoing PD-1 immunotherapy. The platform provides actionable insights that enable oncologists to improve patient outcomes by optimizing treatment strategies based on real-world evidence.

CellRep develops cell reprogramming strategies to enhance T cell functionality, increasing their therapeutic potential for cancer and chronic conditions. The company provides an end-to-end pipeline from target discovery to preclinical validation, enabling more effective cell therapies for patients.

Precision Data provides a business intelligence platform that utilizes generative artificial intelligence to optimize access to over 8 billion lines of structured clinical data, enhancing real-world evidence studies in healthcare. The company addresses the challenge of data quality and accessibility, enabling healthcare organizations to make informed decisions based on accurate and comprehensive information.

The startup develops an AI-driven health tech software that enhances patient-clinic interactions through personalized and secure communication. This solution improves patient engagement and adherence to treatment, leading to better health outcomes in healthcare settings.

The startup develops an artificial intelligence-based respiratory health monitoring system that analyzes individual and population-level respiratory data to track disease progression and treatment outcomes. This technology enables healthcare providers to implement timely interventions for patients with respiratory illnesses, improving overall care quality.

This startup develops artificial intelligence tools tailored for the real estate sector, utilizing machine learning algorithms to analyze market trends and property values. Their solutions enhance decision-making for real estate professionals by providing accurate predictive analytics and streamlined property management processes.

Omni is a digital pharmacy application that provides a flexible medication plan usable at any pharmacy in Brazil, allowing users to manage their health expenses through a simple app interface. The platform utilizes artificial intelligence to interpret medical prescriptions and offers professional health guidance, reducing treatment abandonment and improving chronic condition management for employees.

Onward Assist is a predictive analytics platform that utilizes AI-driven image analysis to enhance cancer diagnosis by identifying biomarkers and reducing reporting time by 30-40%. The platform addresses the lack of effective cancer scoring tools tailored for diverse populations, enabling pathologists to make more accurate treatment decisions efficiently.

The startup is developing a Clinical Digital Twin Platform that creates virtual replicas of patients using real-time health data and advanced modeling techniques. This platform enables healthcare providers to personalize treatment plans and improve patient outcomes by simulating various clinical scenarios.

Proffer is a platform that utilizes artificial intelligence and data science to automate price and discount management for the pharmaceutical retail and distribution sectors. By providing real-time market and competitor data, it enables businesses to optimize pricing strategies, enhancing profitability and competitiveness.

Provides an AI-powered recruiting platform that automates talent attraction and opportunity dissemination, achieving a candidate alignment rate exceeding 92%. This system reduces the hiring process duration by three times, streamlining candidate selection for businesses.

PROSPERiA utilizes artificial intelligence to automatically analyze retinal images, providing personalized recommendations to prevent blindness caused by chronic diseases. The platform enhances early detection and treatment accessibility, addressing the critical issue of late diagnosis in diabetic patients.

The startup offers a cloud-based marketing platform that utilizes AI to provide businesses with qualified lead databases and tailored campaign strategies. This approach enables companies to enhance customer acquisition and generate new sales opportunities without relying on invasive automation techniques.

Guska develops synthetic RNA oncolytic virus therapies that precisely target and eliminate cancer cells while stimulating the immune system. This approach offers a more effective and less harmful alternative to traditional cancer treatments by enhancing the body's ability to fight tumors.

Arvo is a healthcare technology platform that utilizes artificial intelligence and machine learning to detect complex patterns and anomalies in healthcare transactions, preventing fraud, errors, and waste. By processing over R$100 billion in claims data, Arvo enhances operational efficiency and ensures compliance, saving the healthcare industry billions lost to improper reimbursements.

EnCharge AI develops a scalable analog in-memory computing platform that enhances AI performance by achieving 20 times higher efficiency and 10 times lower total cost of ownership compared to traditional GPU solutions. This technology enables on-device processing, significantly reducing CO2 emissions and ensuring data privacy while making advanced AI accessible beyond cloud infrastructure.

Huna develops an AI engine that analyzes routine blood test data to identify risk patterns for early cancer detection and other chronic diseases. This technology enables healthcare providers to classify patients by risk level, improving clinical decision-making and increasing the chances of successful treatment while reducing overall healthcare costs.

SHS Health Tech utilizes artificial intelligence to connect healthcare institutions with suppliers of medical supplies and pharmaceuticals, optimizing procurement processes through data-driven insights. This approach reduces acquisition costs and enhances supply chain efficiency, addressing the challenges of fragmented purchasing and inconsistent supplier relationships in the healthcare sector.

AI-powered real estate marketplace that leverages machine learning algorithms to analyze property data, market trends, and user preferences. It streamlines property discovery and investment by providing personalized recommendations and predictive insights, helping buyers, sellers, and investors make informed decisions in a complex market.

Arkangel AI is a no-code platform that transforms medical data into AI algorithms for early disease detection, enabling healthcare organizations to build and deploy tailored solutions efficiently. By streamlining processes such as patient triage and drug adverse effect prediction, Arkangel AI enhances healthcare outcomes while significantly reducing operational costs.

Rosebud Biosciences develops targeted therapies for rare genetic diseases in children by utilizing organoids that replicate specific genetic mutations, allowing for precise drug screening. This approach addresses the critical lack of approved treatments for 95% of rare diseases, significantly improving the potential for effective cures.

The startup develops a generative artificial intelligence-based medical record system that automates healthcare billing by accurately reading documents and performing billing calculations. This technology reduces errors and processing time, enabling clinics and laboratories to enhance the efficiency of their medical billing operations.

Aperture Therapeutics develops a drug discovery engine that utilizes extensive cell libraries representing genetic diversity to identify gene variants that confer protection against neurodegenerative diseases. By targeting specific RNA transcripts, the company aims to create therapies that can delay brain aging and improve outcomes for affected populations.

The startup develops biological treatments using single-domain antibodies for targeted therapies, focusing on pre-clinical studies to validate therapeutic applications. Their advancements in delivery methods, including topical, inhalation, injectable, and oral administration, enable tailored treatments for specific medical conditions.

Kinzbio develops precision antimicrobial therapies using bacteriophages to target and eliminate specific bacterial pathogens. Their AI-driven platform rapidly identifies and optimizes phages for personalized treatments, offering a highly specific alternative to traditional antibiotics.

Comsentimento develops an AI-driven platform for clinical data transformation and research, focusing on enhancing cancer treatment and facilitating access to clinical trials. The platform provides healthcare professionals with actionable insights and support for chronic disease management, improving patient care and treatment adherence.

Yeda Health utilizes artificial intelligence to provide personalized dietary and lifestyle recommendations based on individual responses to food and continuous glucose monitoring data. This approach addresses the challenge of managing blood glucose levels by recognizing that each person's metabolic response is unique, enabling tailored strategies for metabolic stability.

The startup has developed a clinical research platform that utilizes machine learning to target the biological processes of aging, facilitating the discovery of therapies for age-related diseases such as cardiovascular and neurodegenerative conditions. By enabling pharmaceutical companies to enhance medical treatments, the platform addresses the need for more effective interventions in aging-related health issues.

Blue AI is a no-code AI platform that utilizes machine learning models, primarily XGBoost and natural language processing, to analyze health claims data for employers and healthcare providers in Latin America. It identifies potential fraud, unnecessary procedures, and predicts avoidable hospitalizations, enabling businesses to proactively manage healthcare costs and improve patient care efficiency.

The startup develops an all-in-one AI platform that integrates knowledge engineering into large enterprises through data engineering, customized models, and content creation tools. This technology enables businesses to optimize operations and drive growth by effectively managing and utilizing their data resources.

The startup offers a healthcare platform that utilizes artificial intelligence and data mining to enhance treatment management for patients and medical providers. By enabling patients to identify specialists and appropriate treatments, the platform improves diagnostic analysis and user experience, ultimately reducing the time and resources required for patient care.

The startup offers an AI-driven platform that connects businesses with suitable partners throughout their innovation journey. By leveraging machine learning algorithms, it enhances strategic collaboration, enabling companies to identify and engage with startups that align with their specific needs.

Begen is a platform that connects businesses with specialized AI developers, enabling efficient access to AI solutions while reducing development costs. It addresses the challenge of AI adoption by providing a controlled environment for companies to implement AI-driven innovations and streamline their operations.

The startup develops chip technology that integrates big data analytics and heterogeneous computing to enhance the functionality of the Internet of Things. This technology enables industries, such as automotive and healthcare, to incorporate artificial intelligence into their products and services, improving operational efficiency and decision-making capabilities.

Ai Bruna utilizes artificial intelligence to optimize production processes across various industries by predicting raw material characteristics and enhancing operational efficiency. The platform reduces production costs, energy usage, and waste while improving product quality and profitability through data-driven decision-making.

AIMedic utilizes artificial intelligence to integrate diverse medical data sources, enhancing diagnostic accuracy and treatment selection for healthcare professionals. The platform supports patient monitoring through an intelligent assistant, providing validated educational resources and vital health updates to improve patient outcomes.

The startup operates a healthcare optimization platform that utilizes an algorithm to compare prices and stock levels of medicines across multiple pharmacies. This technology enables consumers to purchase medications at lower prices by streamlining the procurement process and enhancing price transparency.

Base Cientifica offers comprehensive molecular and cellular research services to accelerate preclinical development and personalized medicine. They specialize in biological assay validation, biobanking, and molecular diagnostic assay development using PCR and NGS. Their services also include preclinical efficacy and safety studies, 3D organoid cultivation, and AI-driven R&D optimization.

SIENTIA™ is an AIOps platform that enables the seamless deployment of AI models in Operational Technology environments, transforming Proofs of Concept into production-ready solutions. By integrating industry data, SIENTIA™ accelerates AI scalability and operational efficiency for heavy-asset industries, delivering measurable results in under one second of inference time.

Fauna provides personalized gut health solutions through its gut insight test and prebiotic supplements. The company offers a holistic approach to wellness by analyzing an individual's microbiome and recommending targeted interventions to address root health issues naturally.

The startup operates a genomics platform that centralizes and integrates DNA data to provide precise diagnoses and personalized treatment plans through advanced data analysis and interpretation. By leveraging genomic information, the platform enables researchers to enhance health outcomes and preventive care strategies for individuals.

The startup develops AI-powered applications that enhance decision-making by analyzing large datasets and providing actionable insights. This technology enables organizations to make data-driven choices more efficiently, reducing uncertainty and improving operational outcomes.

The startup develops gene therapies utilizing a biocompatible delivery system to facilitate targeted treatment of genetic diseases. This approach enhances the efficacy of therapeutic interventions, addressing the limitations of traditional treatment methods in the biotechnological market.

Celentis develops novel therapeutic solutions by leveraging advanced biotechnology research. The company focuses on creating innovative treatments for unmet medical needs, aiming to improve patient outcomes.

Speratum Biopharma is developing targeted molecular therapeutics utilizing a proprietary RNA interference (RNAi) mimic of miR-198 for the treatment of solid tumors. The company's approach addresses the need for effective cancer therapies by enhancing the systemic and targeted delivery of oligonucleotides to inhibit tumor growth.

The startup utilizes a proprietary Generative Biology Platform and a Discovery Platform that integrate machine learning and multi-modal single-cell analysis to identify gene regulatory networks and develop targeted cell therapies for cancer. By precisely modulating gene expression in specific cell types, the company aims to enhance the efficacy of cell-based treatments, addressing the limitations of traditional cancer therapies.

Naturannova utilizes a computational platform that combines AI and bioinformatics to identify and analyze plant-based proteins, creating sustainable and clean label ingredients. The startup addresses the need for healthier food options by developing novel protein sources, such as their all-natural protein-based sweetener, through precision fermentation and laboratory testing.